Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.
Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
J Microbiol Immunol Infect. 2024 Oct;57(5):669-684. doi: 10.1016/j.jmii.2024.06.001. Epub 2024 Jun 21.
Herpes zoster (HZ) is a painful, vesicular, cutaneous eruption from reactivation of varicella zoster virus (VZV), which can lead to potentially debilitating complications. The lifetime risk of HZ is estimated to be 20%-30% in the general population, with an increased risk in the elderly and immunocompromised populations. The most effective strategy to prevent HZ and its complications is by vaccination. Two types of HZ vaccines, zoster vaccine live and recombinant zoster vaccine, have been approved for use. This guidance offers recommendations and suggestions for HZ vaccination in adults, aiming to reduce the disease burden of HZ and its complications. It is intended as a guide to first-line healthcare providers, but does not supersede clinical judgement when assessing risk and providing recommendations to individuals. The Working Group on Adult Immunization Practice was appointed by the Infectious Diseases Society of Taiwan (IDST) and recommendations were drafted after a full literature review, using the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. The recommendations were reviewed and revised by expert review panels during a series of consensus meetings and endorsed by the IDST, Taiwan Association of Family Medicine, the Taiwanese Dermatological Association, the Taiwan Oncology Society, the Taiwan Society of Blood and Marrow Transplantation, the Transplantation Society of Taiwan, the Taiwan AIDS Society, and the Taiwan College of Rheumatology. This guidance describes the epidemiology of HZ and provides recommendations for HZ vaccination in adults with varying levels of risk, differing history of previous VZV infection and past varicella or zoster vaccinations.
带状疱疹（HZ）是由水痘带状疱疹病毒（VZV）再激活引起的疼痛性、水疱性皮肤疹，可能导致潜在的致残性并发症。普通人群中 HZ 的终生风险估计为 20%-30%，老年人和免疫功能低下人群的风险增加。预防 HZ 及其并发症的最有效策略是接种疫苗。两种类型的 HZ 疫苗，即水痘带状疱疹活疫苗和重组带状疱疹疫苗，已获准使用。本指南提供了成人 HZ 疫苗接种的建议和建议，旨在减轻 HZ 及其并发症的疾病负担。它旨在作为一线医疗保健提供者的指南，但在评估风险和向个人提供建议时，不应取代临床判断。成人免疫接种实践工作组由台湾传染病学会（IDST）任命，在对完整的文献进行审查后，使用推荐分级的评估、制定与评价（GRADE）系统起草了建议。这些建议在一系列共识会议期间由专家审查小组进行了审查和修订，并得到了 IDST、台湾家庭医学学会、台湾皮肤科医师协会、台湾肿瘤学会、台湾血液与骨髓移植学会、台湾移植学会、台湾爱滋病学会和台湾风湿病学会的认可。本指南描述了 HZ 的流行病学，并针对不同风险水平、既往 VZV 感染和既往水痘或带状疱疹疫苗接种史的成人提供了 HZ 疫苗接种建议。
